cyrilzakka/clinical-trials huggingface dataset:
Investigation of the Effect of Respiratory Exercises on Pain and Functionality in Individuals With Rotator Cuff Syndrome

As it causes pain and disability in individuals with rotator cuff lesions, which is one of the most common causes of shoulder pain, it affects performance in activities of daily living. Shoulder pain significantly affects the quality of life of individuals. The aim of conventional treatment in Rotator Cuff injuries is to reduce the inflammation in the area and to enable the shoulder to perform its normal functions. Conventional treatment is to restore muscle balance in the shoulder area. Muscle balance is achieved by strengthening the teres minor, infraspinatus, and subscapularis, which are also the humeral head depressors, and by strengthening the serratus anterior, levator scapula. For strengthening, the shoulder must have a full range of motion. In our study, stretching exercises, cold pack, Ultrasound, TENS, wand, and Codman exercises, which are classical physiotherapy methods, will be applied to all three groups. There are also studies in the literature investigating the effects of traditional physiotherapy methods on individuals with shoulder Rotator Cuff syndrome. The benefits of breathing exercises on pain, shoulder joint range of motion, and balance have all been researched in the literature. Increased diaphragm activity also guarantees that posture and body positions are maintained healthily. Diaphragm activity generally alters how an individual perceives pain. Diaphragmatic breathing is a therapeutic approach for musculoskeletal disorders.

Breathing techniques have been demonstrated to reduce shoulder pain and increase ROM at the literature. However, no study has been found on the effectiveness of breathing exercises applied in addition to conventional physiotherapy in individuals with Rotator Cuff syndrome.

Based on all of this knowledge, it was designed for this study to examine the efficacy of breathing exercises used in combination with traditional physiotherapy in patients with Rotator Cuff syndrome.

Eligibility Criteria:
Inclusion Criteria:

1. Restricted shoulder joint range of motion
2. Having Rotator Cuff Syndrome
3. Not having had any shoulder surgery
4. Being between the ages of 18 - 65

Exclusion Criteria:

1. Major trauma to the shoulder
2. Anatomical deformities and skeletal system fractures
3. Diagnosed orthopedic or rheumatological diseases
4. Being included in a physiotherapy program in the last 6 months
5. Having a cardiac pacemaker
6. Presence of active infection
7. Myocardial infarction in the last 6 months
8. Participants who have any illness that prevents them from doing the exercises will be excluded from the study.
Esophageal Stump Washout

Intraluminally shed viable tumor cells might contribute to local recurrence in cancer of the esophagus and the cardia. The aim of the the study was to establish a method of mechanical lavage of the remaining part of the esophagus and, hence, to reduce the intraluminal cancer cells before doing the esophageal anastomosis.

See study protocol!

Eligibility Criteria:
Inclusion Criteria:

* histologically confirmed cancer of gastro-esophageal junction with indication for surgery

Exclusion Criteria:

* missing informed consent
The Correlation Between Ultrasonography Based Muscle Architecture Parameters and Voluntary Isometric Muscle Strength

The goal of this study is to investigate potential relations of ultrasound-based muscle architecture parameters and isometric knee flexor muscle strength (IKFS) in healthy individuals. IKFS was measured for twenty participants (22.15±2.41 y.o; 8 females, 12 males) by a hand-held dynamometer. Investigated parameters were total and individual cross-sectional areas (CSA), Muscle-Thickness (MT), and pennation-angle (PA) for Biceps Femoris-long head (LBF), Semitendinosus (ST) and Semimembranosus (SM) muscles at 25%, 50% and 75% length of the thigh.

The images of hamstring muscles were taken by a US device (Toshiba Aplio 500, Japan) with a linear probe (10-12 MHz, with a footprint of 52 mm).

For each participant, maximum voluntary IKFS was measured from the non-dominant side in the prone position with foot and ankle stayed outside of the bed. Maximum IKFS (20 limbs) was measured by an HHD (A Lafayette Model 01165) (Lafayette, IN) at 15° knee flexion in prone lying position

Eligibility Criteria:
Inclusion Criteria:

* being healthy young

Exclusion Criteria:

-
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.


Eligibility Criteria:
Inclusion Criteria:

* A diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.
* Moderate to severe chronic plaque psoriasis at both Screening and Baseline (Randomization) Visits
* Candidates for systemic therapy or phototherapy for psoriasis treatment as assessed by the investigator

Exclusion Criteria:

* Prior therapy with an anti-interleukin (IL)-17 or anti-IL12/23p40 or anti-IL-23p19 inhibitor
* Concurrent therapy with a biologic and/or other systemic therapy
Continuing Evaluation of the LungPoint ATV System

The purpose of this study is to evaluate the safety and performance of the LungPoint ATV System in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer.

The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs. This feasibility study is being conducted to assess the safety and yield of the LungPoint ATV System in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer. Navigation to and sampling of the patient's lung cancer tumor is conducted.

Eligibility Criteria:
Inclusion Criteria:

1. Surgical candidates age 21-75 years at screening
2. Highly suspicious SPN, defined as distinct nodule with a diameter of 10-30 mm in its largest dimension
3. No known endobronchial tumor
4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE.
5. Willing to participate in all aspects of study protocol for duration of study
6. Able to understand study requirements
7. Signs study-related informed consent document

Exclusion Criteria:

1. Any contraindication to bronchoscopy, for example: (a.) Untreatable life-threatening arrhythmias, (b.) Inability to adequately oxygenate the patient during the procedure, (c.) Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated), (d.) Recent myocardial infarction, (e.) Previously diagnosed high-grade tracheal obstruction, (f.) Uncorrectable coagulopathy.
2. Known coagulopathy
3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3
4. History of major bleeding with bronchoscopy
5. Pulmonary hypertension with mean PAP \>25 mm
6. Moderate-to-severe pulmonary fibrosis
7. Moderate to severe emphysema or COPD with FEV1 \<60% predicted or RV \>200% predicted
8. Bullae \>5 cm located in vicinity of target SPN or ATV tunnel
9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: (a.) ASA class \> 3, (b.) \> stage 3 heart failure, (c.) severe cachexia, (d.) severe respiratory insufficiency or hypoxia
10. Ongoing systemic infection
11. Contraindication to general anesthesia
12. Chronic use of anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel)
13. Participation in any other study in last 30 days
14. Prior thoracic surgery on the same side of the lung as the SPN
15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.
16. Life expectancy of less than one year.
17. Patients with known intrapulmonary metastases of extrapulmonary cancer/tumors
18. Scheduled for lung surgery within 7 days post-scheduled diagnostic bronchoscopy
Dexmedetomidine Vs Dexamethasone in Popliteal Nerve Block

Effect of Perineural Dexmedetomidine vs. Dexamethasone on the duration of popliteal nerve block for Anesthesia After Pediatric ankle/foot surgery.

This study is proposed to explore the effect of systemic Dexamethasone on the duration of popliteal block for analgesia after pediatric ankle surgery.

After ankle/foot surgery, children need good analgesia. Peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe.

The safety of local anaesthesia is essential in children due to the much lower toxicity threshold of local anaesthetics. An effective adjuvant, such as Dexamethasone, could allow for a higher dilution of local anaesthetics while maintaining and enhancing their analgesic effect.

There is considerable research where intravenous and perineural dexamethasone use has been compared in adults. However, there is a massive lack of research regarding children.

In this study, investigators compare perineural Dexmedetomidine and Dexamethasone. Group 2 will have Dexamethasone in a 0.1mg/kg dose, and group 2 will have dexmedetomidine in a 0.5 ug/kg dose added to the local anaesthetic in peripheral nerve block.

The investigator's goal is to find which perineural adjuvant, Dexamethasone or dexmedetomidine, covers the need for good pain relief and fast recovery postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* children scheduled for foot/ankle surgery
* body weight \> 5kg

Exclusion Criteria:

* infection at the site of the regional blockade
* coagulation disorders
* immunodeficiency
* ASA= or \>4
* steroid medication in regular use
31P-MRS and Huntington Disease

The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.


Eligibility Criteria:
Inclusion Criteria:

* 5\<UHDRS\<50
* Age\>18 years
* Ability to undergo MR scanning
* Covered by french social security

Exclusion Criteria:

* Evidence of psychiatric disorder
* Attendant neurological disorder
* Contraindications to MRI (claustrophobia, metallic or material implants)
* Severe head injury
* Unable to understand the protocol
* Pregnancy
* Failure to give informed consent
* Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
* Unwillingness to be informed in case of abnormal MRI
Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteers

Aim: To study the stability of brain MR-scanning parameters (blood-flow, microstructure, volume, metabolism) over 1 week in health volunteers.

Hypothesis: MR-scanning parameters are stable over 1 week in healthy volunteers


Eligibility Criteria:
Inclusion Criteria:

* age 18-65
* oral and written consent

Exclusion Criteria:

* intracranial disease
* previous intracranial surgery
* magnetic implant or magnetic foreign body
* claustrophobia
Neuromodulation of Executive Function in the ADHD Brain

This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD compared to healthy controls.

This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD. Deficits in these cognitive functions are core to ADHD, and cause significant impairment and morbidity. The study will also include a cohort of healthy controls for comparison.

Eligibility Criteria:
Inclusion Criteria

1. Male and female subjects 18-66 years of age
2. Healthy volunteers or volunteers with a diagnosis of ADHD in adulthood, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) \[American Psychiatric Association, 2013\] criteria, including at least 5 moderate inattentive or impulsive-hyperactive symptoms, and onset of two symptoms of inattentive or of impulsive/hyperactive traits by the age of 12.
3. Patient will be either off stimulant medications or, if undergoing treatment with stimulants, will be asked to discontinue two days prior to the experiment, under physician-guided protocol, and allowed to resume afterwards. Subjects may resume stimulant use between the two study visits so long as they discontinue use two days prior to the second study visit. If fatigue is problematic in subjects discontinuing medication, they will be allowed to continue with the study if they are able to follow the suggested taper plan (50% of the dose day one, 25% dose day 2, stop day of visit (day 3)).
4. English-speaking

Exclusion Criteria

1. Current or past history of clinically unstable psychiatric conditions such as suicidal or homicidal behavior or psychotic disorders.
2. Pregnant or nursing females.
3. Inability to participate in testing procedures
4. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
5. Additional exclusion criteria for healthy controls:

   1. Diagnosis of psychiatric of neurological disorder
   2. Ongoing treatment with any psychotropic medications.
Remifentanil vs Fentanyl During Cardiac Surgery and Chronic Thoracic Pain

This study will investigate the influence of intra-operative use of remifentanil versus fentanyl on the percentage of patients with chronic thoracic after cardiac surgery via sternotomy. Secondary quantitative sensory testing is performed to determine thermal and electrical detection and pain threshold and the difference in pain variability scoring. Postoperative pain scores, analgesic use, genetic variances and costs are measured.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing cardiac surgery via sternotomy (Coronary artery bypass graft (CABG) and/or valve replacement)
* Patients admitted to the ICU or PACU in the St. Antonius hospital
* Patients between 18 and 85 years old
* Patients weighing between 45 and 140 kg
* Written informed consent

Exclusion Criteria:

* Pregnancy/ breastfeeding
* Language barrier
* History of drug abuse
* Neurologic condition such as peripheral neuropathy
* Known remifentanil, fentanyl, morphine or paracetamol allergy
* Body Mass Index (BMI) \> 35 kg/m2
* Prior cardiac surgery (re-operations);
* Patients with chronic pain conditions.
Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery

Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.


Eligibility Criteria:
Inclusion Criteria:

1.Pathologically diagnosed as sinonasal malignant mucosal melanoma, locally resectable and no contraindication for surgery or radiation. 2.T3 and T4. 3.Age ≥18 year-old 4.No distant metastasis 5.No head and neck radiation and systemic anti-tumor therapy performed in the past 5 years. 6.The performance status of the Eastern Cooperative Oncology Group(ECOG) is 0-2 points and surgery after general anesthesia and postoperative radiation could be tolerated. 7.Accepted organ function

Exclusion Criteria:

1. Patients who refused to sign informed consent. 2. Have received radioactive seed implantation in the treatment area. 3. Suffer from uncontrolled disease which could interfere treatment. 4. Suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.). 5. The patient has surgical contraindications: such as severe cardiopulmonary disease, coagulation dysfunction and so on. 6.The patients have autoimmune diseases. 7. The patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before the first administration; 8. Severe allergic reaction to other monoclonal antibodies; 9. Previously received PD-1 monoclonal antibody, CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway) treatment; 10. Live vaccines have been inoculated within 4 weeks before the first administration or during the study period; 11. The patient has any situation that may hinder study compliance or the safety during the study period.12. Existence of serious neurological or psychiatric diseases, such as dementia and seizures; 13. Uncontrolled active infection. 14. Pregnant or breastfeeding women. 15. Those who have no personal freedom and independent capacity for civil conduct;p. 16. There are other situations that are not suitable for entry into the study.
PRO 140 by IV Administration in Adults With HIV-1 Infection

The purpose of this study is:

1. To assess and characterize the PK and PD of PRO 140 administered IV
2. To assess the antiviral activity of PRO 140
3. To assess the safety and tolerability of PRO 140


Eligibility Criteria:
Inclusion Criteria:

1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
3. CD4+ T-lymphocyte cell count ≥ 300 cells/mm3 and no documented count \< or = 250 cells/mm3
4. Has not taken any anti-retroviral therapy (ART) w/in 12 wks of Early Screening Visit
5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit
6. Clinically normal or "not clinically significant (NCS)" resting electrocardiogram
7. Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit \& a negative urine pregnancy test w/in 72 hrs prior to first dose of study medication, \& be non-lactating. Male \& female subjects must agree not to participate in a conception process from Early Screening Visit through Day 59.

Exclusion Criteria:

1. CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.
2. Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant during the study.
3. History of active hepatitis within the previous 24 wks
4. Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, experimental or approved.
Specific Neurotechnical Strength Training (NeuroTraining)

This study aims to apply a novel study methodology using high density electromyography (HDEMG) to know what are the mechanisms underlying the structural and functional changes obtained by two different training methods, commonly used, facilitating their understanding, study and subsequent application according to specific needs.

Different training methodologies have previously shown similar results in the improvement of structural or functional characteristics such as hypertrophy or strength. However, the different nature of their methods has suggested for years the possibility that different neuromuscular mechanisms could be behind these observed characteristics.

The development of a new technology, such as high-density electromyography (HDEMG), capable of studying new properties previously hidden from assessment methods, such as the speed of nerve impulse propagation or the frequency of motor unit discharge, has allowed a more thorough study of the mechanisms.

This study aims to apply this new study methodology to know what are the mechanisms underlying the changes at the structural and functional level obtained by two different training methods, commonly used, facilitating their understanding, study and subsequent application according to specific needs.

For this reason, the main hypothesis is the generation of different neuromuscular mechanisms and adaptations by executing, for 4 weeks, two different training methodologies, obtaining a dissociation between the results obtained at the structural level (hypertrophy), functional (generation of strength) and HDEMG analysis of the central and peripheral characteristics of the neuromuscular system in each of the programs studied.

Eligibility Criteria:
Inclusion Criteria:

* 18-35 years
* men

Exclusion Criteria:

* physical exercise that involves work of upper limbs during the time of the intervention
* upper limb injury during the previous 12 months
* systemic diseases
Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates

The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. We performed a retrospective 12-month audit to assess the efficacy and safety of the FAc implant in our clinical practice.

Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to evaluate functional and anatomical characteristics and outcomes (visual acuity \[VA; ETDRS letters score\], central macular thickness \[CMT\] and intraocular pressure \[IOP\]) at baseline, weeks 2-4 and months 3, 6 and 12 months.

Eligibility Criteria:
Inclusion Criteria:

* DME
* Pseudophakic

Exclusion Criteria:

* Other causes of macular edema.
* Phakic
* Know case of gaucoma
A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants

The main goals of the study are to assess uptake and distribution of Lu AF88370 in the brain when given at tracer levels (microdose) in healthy young men.


Eligibility Criteria:
Inclusion Criteria:

* The participant has a body mass index (BMI) ≥18.5 and ≤30.0 kilograms (kg)/square meter (m\^2) at the Screening Visit.
* The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical and neurological examination, vital signs, an ECG, and the results of the clinical chemistry, hematology, urinalysis, serology, and other laboratory tests.

Exclusion Criteria:

* The participant has taken disallowed medication \<1 week prior to the first dose of study drug or \<5 half-lives prior to the Screening Visit for any medication taken.
* The participant has received a COVID-19 vaccination within the last 30 days before receiving first dose of study drug.
* The participant has had surgery or trauma with significant blood loss \<6 months prior to the first dose of the study drug.
* The participant is exposed to significant levels of ionising radiation at work.

Note: Other inclusion and exclusion criteria may apply.